Nihon Kagaku Sangyo Co., Ltd.

4094.T
Specialty Chemicals
2026/11/09 12:01 Updated
Market Cap: $243.1M (¥38.5B)
Stock Price: $12.47 (¥1,973)
Exchange Rate: 1 USD = ¥158.23

Fiscal Year Ending March 2027 Q2 (Interim) Financial Summary [Japanese GAAP] (Consolidated)

For the interim period of the fiscal year ending March 2027, consolidated net sales were 15,119 million yen, up 13.8% year-over-year. Operating income was 1,303 million yen, down 14.1%, ordinary income was 1,727 million yen, and net income attributable to owners of the parent for the interim period was 1,195 million yen. The full-year forecast has been revised and published: net sales 29,830 million yen, operating income 1,800 million yen, ordinary income 2,500 million yen, and net income 1,780 million yen. The company operates two segments—Pharmaceuticals and Building Materials—with segment sales of 13,005 million yen and 2,113 million yen respectively; segment income was 1,445 million yen for Pharmaceuticals and 402 million yen for Building Materials.

Importance:
Page Updated: November 9, 2026
IR Disclosure Date: November 9, 2026

Key Figures

  • Net Sales: 15,119 million yen (YoY +13.8%)
  • Operating Income: 1,303 million yen (YoY -14.1%)
  • Net Income Attributable to Owners of Parent (Interim): 1,195 million yen (YoY -4.6%)
  • Full-year Forecast: Net Sales 29,830 million yen, Operating Income 1,800 million yen, Ordinary Income 2,500 million yen, Net Income 1,780 million yen
  • Segment Net Sales: Pharmaceuticals 13,005 million yen, Building Materials 2,113 million yen
  • Segment Income: Pharmaceuticals 1,445 million yen, Building Materials 402 million yen

AI要約

Overview of Results

For the interim period of the fiscal year ending March 2027, net sales totaled 1,511,904 thousand yen, an increase of 13.8% year-over-year. However, operating income declined due to increased investment in the recycling business and higher expenses for new business development. Ordinary income decreased slightly; despite the recognition of extraordinary gains, overall sales growth was maintained. By segment, the Pharmaceuticals business performed strongly, while the Building Materials business achieved higher sales and profits amid mixed demand and cost factors.

Outlook and Capital Allocation

The full-year earnings forecast has been updated: net sales are expected to be 29,830 million yen, operating income 1,800 million yen, ordinary income 2,500 million yen, and net income attributable to owners of the parent 1,780 million yen. Growth investments in new businesses such as lithium-ion battery recycling are expected to continue, though sales expansion may be affected by higher raw material costs. The financial position is stable with a shareholders' equity ratio of 83.9%, and cash flows are influenced by multiple factors including changes in interest-bearing debt.

Net Sales Trend

Operating Income Trend

Segment Net Sales Ratio

Segment Operating Margin

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Nihon Kagaku Sangyo Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →